Home Blog Page 1250

Shopware Announces New “B2B Ecommerce Compass 2026” Whitepaper and “B2B Future Forum” Webinar Series to Guide Merchants Into the Future

SCHÖPPINGEN, Germany, Jan. 20, 2026 /PRNewswire/ — Shopware, a leading global ecommerce platform provider, is reinforcing its role as a strategic thought leader in B2B commerce with the release of its new whitepaper “B2B Ecommerce Compass 2026,” alongside a new webinar series, “B2B Future Forum.

As the B2B ecommerce landscape approaches a critical turning point, Shopware aims to provide in-depth knowledge, practical insights, and concrete recommendations to help companies future-proof their B2B business.

The whitepaper and webinar series is a part of Shopware’s broader commitment to bringing the whole industry forward, offering tangible takeaways and actionable guidance for merchants to future proof their offering in today’s increasingly complex market environment.

B2B Ecommerce Compass 2026: Guidance in a Market Under Pressure

Despite having established digital sales channels, many B2B companies continue to struggle with fragmented systems, inconsistent data, and a high level of manual effort. Simultaneously, B2B customers increasingly expect transparent pricing, reliable delivery timelines, and seamless, omnichannel purchasing experiences.

The free whitepaper dives deeper into how successful B2B commerce is built on digital maturity and a stable, scalable commerce architecture. Readers will learn more about the current state of B2B ecommerce in 2026, key market developments and structural challenges, priority action areas, real-world examples from complex B2B environments, and get an outlook of the industry for 2026 and beyond.

Interested parties can download the whitepaper here.

B2B Future Forum: A Webinar Series for Strategic Decision-Makers

In addition to the free whitepaper, Shopware is launching the B2B Future Forum, a bi-weekly, five-episode live webinar series. Each episode will examine how B2B commerce is evolving, which developments truly matter, and how companies can respond strategically.

The series focuses on growth strategies, reducing operational friction, and building future-ready commerce architectures.

Episodes start on January 27, and topics include:

  • The B2B commerce wake-up call: Why buyers expect more in 2026
  • More B2B revenue with less sales employees
  • Building adaptable commerce: How B2B leaders turn fragmented systems into growth engines
  • The experience gap: Why B2B buyers leave – even when your product is better
  • The real ROI of modern commerce: What 100 B2B leaders learned about TCO and flexibility

More information and registration details for the webinar series can be found here.

Life’s Moments App Launches Worldwide on iPhone and Android — Turning Scattered Photos, Family Memories and Pet Moments into One Organized Family Tree

All Your Family’s Memories… Finally Organized

ADELAIDE, Australia, Jan. 20, 2026 /PRNewswire/ — Life’s Moments App today announced its global launch on iPhone and Android, giving families and pet owners an intuitive way to capture, store and organize photos, videos, milestones and important records — all in one secure digital Family Tree, designed to be handed down to the next generation.

Your family's memories... all in one place.
Your family’s memories… all in one place.

Built around a dynamic Family Tree, Life’s Moments App allows users to collect meaningful memories and share them with invited family members anywhere in the world — helping families stay connected across generations. Designed to reflect modern families, the app enables users to add children, relatives and pets, ensuring every important life moment is preserved.

The launch is perfectly timed for those looking to organize all of the holiday photos they’ve just taken.

Recognizing that pets are family too, Life’s Moments App includes dedicated pet profiles that function as a complete digital life record. Pet owners can document adoption or “gotcha” days, birthdays, training milestones, favorite routines and everyday memories — all personalized with captions and notes. Users can also invite partners, family members or carers to view their pet’s profile using customized permissions and share photos and videos of their loved ones directly to their favorite social media platforms from within the app.

A standout feature of Life’s Moments App is its Interview Tool, which provides tailored questions parents can use to record their child on each birthday from infancy through to age 18. These recordings are saved as a digital time capsule — creating deeply personal keepsakes to be cherished in later life.

The app includes a powerful Built-in Scanner, enabling users to digitize and securely store important documents such as awards, report cards, medical records, vaccination certificates and insurance documents directly within a person’s or pet’s profile. Older printed photos can also be converted into digital format, helping families preserve keepsakes currently sitting in boxes or frames.

Unlike short-term photo storage apps, Life’s Moments App has been designed with legacy in mind.  The app introduces a unique Handover Process, allowing members to pass a tailored copy of their Family Tree to the next generation via a personal invitation. For many families, Life’s Moments will become a digital heirloom — a way to ensure stories, photos and milestones don’t disappear across devices, generations or platforms, making Life’s Moments a truly long-term app for families.

Adding a lighter touch, the app includes a dedicated folder for those embarrassing photos — safely tucked away and easy to retrieve for 18th or 21st birthday celebrations.

Looking ahead, Life’s Moments plans to introduce a built-in Print Shop, offering products such as photobooks, sticker sheets and coffee mugs, as well as the Dandelion Club, providing members with access to negotiated discounts on baby and pet products.

The ad-free app offers unlimited storage and supports 12 languages, enabling families to share memories in the language that feels most natural to them. Life’s Moments App is available worldwide via subscription with a genuine 30-day free trial, followed by USD $4.99 per month or $44.99 per year.

Founder Andrew Flynn said:

“Most families take thousands of photos, but very few of those memories survive long enough to be passed down.”

“I wanted to create an all-inclusive app where families can capture, store and organize their life’s moments all in one place — something useful day to day, meaningful over time, and valuable enough to be passed down to future generations. Pets are part of that story too. Their memories matter just as much.”

Life’s Moments… all your memories… finally in one place.

Media Kit:
(Includes – Crib Sheet, Media Quotes, Founder’s Statement, Logos, Videos, Lifestyle & App Screens Photos)
https://tinyurl.com/Lifes-Moments-Media-Kit

Website:
https://lifesmomentsapp.com

Email:
enquiries@lifesmomentsapp.com

Google Play Store:
https://tinyurl.com/Lifes-Moments-Google

Apple App Store:
https://tinyurl.com/Lifes-Moments-Apple

Memories today. Keepsakes tomorrow.
Memories today. Keepsakes tomorrow.

The story is already happening — capture life’s moments now.
The story is already happening — capture life’s moments now.

HR Path strengthens its North American Dayforce practice through its merger with Enforce

PARIS, Jan. 20, 2026 /PRNewswire/ — HR Path, a global leader in HR consulting, digital transformation, and payroll outsourcing, is pleased to announce the merger of its operations with Enforce, a Dallas based HRIS specialist recognized for its strong expertise in Dayforce.

With a presence in 28 countries and a team of over 2,500 professionals, HR Path is a trusted partner for businesses navigating the complexities of Human Resources. Specializing in advisory, implementation, and operational services, HR Path delivers cutting-edge solutions designed to enhance efficiency and foster growth. Since its founding in 2001, the company has remained steadfast in its mission to transform HR practices globally.

Enforce, headquartered in Dallas, Texas, employs a team of 38 Dayforce subject matter experts and supports a large portfolio of clients, primarily in North America. The company is vertically integrated across all Dayforce functional domains and offers a comprehensive suite of Dayforce services, including Implementation, Optimization, Post Go-Live Support, and Outsourced Admin Services. Since its founding more than 10 years ago, Enforce has earned a strong reputation for successfully guiding organizations through Dayforce transformations.

This merger marks a new and strategic step in HR Path’s growth in North America and significantly strengthens its service capabilities around Dayforce, formerly known as Ceridian. HR Path already operates a growing Dayforce practice in the UK & Ireland, and through its acquisition of ClearCourse, has expanded its expertise in the Dayforce ecosystem. With this merger, HR Path will now also offer payroll outsourcing services in the U.S. not only on SAP technologies but now also on Dayforce.

“The merger with Enforce reinforces our commitment to developing a worldclass Dayforce practice,” said François Boulet, Co-CEO of HR Path. “Enforce’s recognized expertise in the U.S. market, combined with HR Path’s global footprint and payroll outsourcing capabilities, will allow us to better support Dayforce customers across the full HR value chain—from advisory to implementation to managed services.”

“Joining HR Path represents an honor and an exceptional opportunity for our team and our clients,” said Michael McKay, CEO and Co-Founder of Enforce and newly appointed HR Path Partner. “By combining Enforce’s exclusive focus and expertise on the Dayforce platform with HR Path’s scale and global presence, we will accelerate our growth and deliver even greater value to organizations adopting Dayforce worldwide.”

PDF: https://mma.prnewswire.com/media/2863619/HR_Path_Enforce_EN.pdf

Contact:
Fabienne Latour
fabienne.latour@hr-path.com

Everclear Launches Cross-Chain Asset Settlement to Streamline Onboarding, Liquidity Efficiency, and Asset Flow into the Mantle Ecosystem

DUBAI, UAE, Jan. 20, 2026 /PRNewswire/ — Mantle, the high-performance distribution and liquidity layer bridging traditional finance (TradFi), real-world assets (RWAs) and on-chain liquidity, today announced a new collaboration with Everclear, introducing Cross-Chain Asset Settlement to the Mantle ecosystem that allows users to seamlessly swap wETH from Ethereum, Arbitrum, Base, or Polygon directly into mETH on Mantle — without traditional bridging friction.

Everclear Launches Cross-Chain Asset Settlement to Streamline Onboarding, Liquidity Efficiency, and Asset Flow into the Mantle Ecosystem
Everclear Launches Cross-Chain Asset Settlement to Streamline Onboarding, Liquidity Efficiency, and Asset Flow into the Mantle Ecosystem

This integration addresses one of the most pressing challenges in multi-chain DeFi: liquidity fragmentation across multiple representations of the same asset.

Solving Fragmentation with Cross-Chain Netting & Settlement

As ecosystems scale, assets like ETH and USD now exist in many forms, from wETH, mETH, stETH to an expanding set of stablecoins. Everclear’s clearing and settlement infrastructure solves this fragmentation by netting cross-chain flows and automatically rebalancing inventory, reducing redundant liquidity and lowering costs.

With this launch, users can access Mantle directly using assets they already hold, while Everclear handles settlement and rebalancing behind the scenes.

“Real-world usability of on-chain assets depends on efficient settlement across chains,” said Emily Bao, Key Advisor of Mantle. “This integration reinforces Mantle’s RWA and ETH-native strategy by removing onboarding friction and enabling capital to flow into the ecosystem in a more scalable, institutional-grade way.”

How It Works: wETH → mETH in Under One Minute

Users holding wETH on supported chains can select Mantle as the destination and receive mETH on Mantle in a single transaction, typically in under one minute.

Everclear’s solver infrastructure fills user intents immediately, while netting and rebalancing cross-chain flows in the background to restore inventory at the lowest possible cost — delivering better pricing, no slippage, and fast execution.

“Everclear was built to be the settlement layer for a fragmented, multi-asset future,” said Nikita Bulgakov from Everclear Foundation. “By connecting different representations of the same asset, we enable partners like Mantle and mETH Protocol to offer a truly chain-abstracted experience to users.”

Unlocking Capital-Efficient Access to Mantle’s Ecosystem

Starting with mETH, this collaboration allows users to enter Mantle’s ecosystem without manually bridging or swapping assets, a key barrier for both retail and advanced users.

Key benefits include:

  • Seamless onboarding into Mantle from major Ethereum ecosystems
  • Improved liquidity efficiency through netting and clearing
  • Faster settlement with capital-efficient execution
  • A foundation for expanding to more ETH-based and stable assets

A Foundation for Chain-Abstracted Finance

Mantle is the first launch partner for Everclear’s expanded cross-asset settlement initiative, with future plans to support additional ETH-based assets, stablecoins, and new chains.

This collaboration reflects a broader industry shift toward chain-abstracted finance, where users interact with assets and applications without needing to manage the complexity of bridges, liquidity pools, or fragmented representations.

About Mantle

Mantle positions itself as the premier distribution layer and gateway for institutions and TradFi to connect with on-chain liquidity and access real-world assets, powering how real-world finance flows.

With over $4B+ in community-owned assets, Mantle combines credibility, liquidity and scalability with institutional-grade infrastructure to support large-scale adoption. The ecosystem is anchored by $MNT within Bybit, and built out through core ecosystem projects like mETH, fBTC, MI4 and more. This is complemented by Mantle Network’s partnerships with leading issuers and protocols such as Ethena USDe, Ondo USDY, and OP-Succinct.

For more information about Mantle, please visit: mantle.xyz
For more social updates, please follow: Mantle Official X & Mantle Community Channel 
For media enquiries, please contact: contact@mantle.xyz

About Everclear

Everclear (formerly Connext) is an interoperability protocol focused on crosschain settlement and liquidity rebalancing for professional users, including market makers, solvers, bridges, and exchanges. Operating as a highly efficient B2B clearing and settlement layer, Everclear powers leading partners such as Across, Relay, LI.FI, Eco, and others, processing approximately $400M in monthly volume across blue-chip assets and stablecoins.

Everclear recently launched Crosschain Asset Settlement and offers custom interoperability solutions, including white-label crosschain deposits, staking, and tailored flows—enabling partners to efficiently attract users and liquidity from long-tail chains.

About mETH Protocol

mETH Protocol is a vertically integrated liquid staking and restaking protocol incubated by Mantle, operating at the intersection of DeFi composability and institutional-grade ETH yield access. With a peak total value locked (TVL) of $2.19 billion achieved within its first year, mETH Protocol is supported by leading validator and custody partners, including P2P, Kraken Staked, OSL, and Copper. The protocol is embedded across over 40+ leading DeFi and exchange platforms such as Bybit, Ethena, and more, whilst incorporated in treasury frameworks for DAOs and corporates as a core liquidity and yield layer.

Netflix and Warner Bros. Discovery Amend Agreement to All-Cash Transaction

All-Cash Structure Increases Value Certainty for WBD Stockholders, Accelerates WBD Stockholder Vote and Underscores Netflix’s Financial Strength

WBD Files Preliminary Proxy Statement for Transaction Approval

HOLLYWOOD, Calif. and NEW YORK, Jan. 20, 2026 /PRNewswire/ — Netflix, Inc. (NASDAQ:NFLX) (“Netflix”) and Warner Bros. Discovery, Inc. (“WBD” or “Warner Bros. Discovery”) announced they have amended their definitive agreement for Netflix’s pending acquisition of Warner Bros. to an all-cash transaction. The revised agreement simplifies the transaction structure, provides greater certainty of value for WBD stockholders, and accelerates the path to a WBD stockholder vote.

The all-cash transaction continues to be valued at $27.75 per WBD share, unchanged from the prior transaction structure. WBD stockholders will also receive the additional value of shares of Discovery Global following its separation from WBD. The transaction will be financed through a combination of cash on hand, available credit facilities and committed financing.

The revised structure enhances execution certainty, aligns with Netflix’s disciplined capital allocation framework and provides clear benefits, including:

  • Greater Value Certainty: The all-cash transaction provides enhanced certainty around the value WBD stockholders will receive at closing, eliminating market-based variability.
  • Faster Path to Stockholder Vote: The revised transaction structure is expected to enable WBD stockholders to vote on the proposed transaction by April 2026. To support this accelerated timeline, WBD has today filed its preliminary proxy statement with the SEC. 

Netflix’s strong cash flow generation supports the revised all-cash transaction structure while preserving a healthy balance sheet and flexibility to capitalize on future strategic priorities.

“Today’s revised merger agreement brings us even closer to combining two of the greatest storytelling companies in the world and with it even more people enjoying the entertainment they love to watch the most,” said David Zaslav, President and CEO of Warner Bros. Discovery. “By coming together with Netflix, we will combine the stories Warner Bros. has told that have captured the world’s attention for more than a century and ensure audiences continue to enjoy them for generations to come.”

“The WBD Board continues to support and unanimously recommend our transaction, and we are confident that it will deliver the best outcome for stockholders, consumers, creators and the broader entertainment community,” said Ted Sarandos, co-CEO of Netflix. “Our revised all-cash agreement will enable an expedited timeline to a stockholder vote and provide greater financial certainty at $27.75 per share in cash, plus the value from the planned separation of Discovery Global. Together, Netflix and Warner Bros. will deliver broader choice and greater value to audiences worldwide, enhancing access to world-class television and film both at home and in theaters. The acquisition will also significantly expand U.S. production capacity and investment in original programming, driving job creation and long-term industry growth.”  

“Over the last decade, when much of the entertainment industry has contracted, Netflix has grown and invested tremendously in the business of film and television in the U.S. and abroad. This transaction will further fuel that growth and investment,” said Greg Peters, co-CEO of Netflix. “By amending our agreement today, we are underscoring what we have believed all along: not only does our transaction provide superior stockholder value, it is also fundamentally pro-consumer, pro-innovation, pro-creator and pro-growth. Our revised all-cash agreement demonstrates our commitment to the transaction with Warner Bros. and provides WBD stockholders with an accelerated process and the financial certainty of cash consideration, while maintaining our commitment to a healthy balance sheet and our solid investment grade ratings. We will continue to work closely with WBD to successfully complete the transaction as we remain focused on our mission to entertain the world and, together, define the next century of storytelling.”

“Our amended agreement with Netflix is a testament to the Board’s unrelenting focus on representing and advancing our stockholders’ interests,” said Samuel A. Di Piazza, Jr., Chair of the Warner Bros. Discovery Board of Directors. “By transitioning to  all-cash consideration, we can now deliver the incredible value of our combination with Netflix at even greater levels of certainty, while providing our stockholders  the opportunity to participate in management’s strategic plans to realize the value of Discovery Global’s iconic brands and global reach. We look forward to continuing to engage with our investors about the compelling benefits of the transaction as we progress toward our stockholder  vote on an accelerated timeline.”

As previously announced, WBD will separate Warner Bros. and Discovery Global into two separate publicly traded companies. This separation is expected to be completed in six to nine months, prior to the closing of the proposed Netflix and Warner Bros. transaction. 

The amended, all-cash transaction was unanimously approved by the Boards of Directors of both Netflix and WBD. Closing remains subject to completion of the Discovery Global separation, receipt of required regulatory approvals, approval of WBD stockholders and other customary closing conditions. The financing structure is not subject to review by the Committee on Foreign Investment in the United States (CFIUS). 

Netflix and WBD have each submitted their Hart-Scott-Rodino (HSR) filings and are engaging with competition authorities, including the U.S. Department of Justice and European Commission. Netflix and WBD remain committed to working closely with regulators and all stakeholders to ensure a smooth and successful transaction. As previously disclosed, the transaction is expected to close 12-18 months from the date that Netflix and WBD originally entered into their merger agreement.

Advisors
Moelis & Company LLC is acting as Netflix’s financial advisor and Skadden, Arps, Slate, Meagher & Flom LLP is serving as legal counsel. Wells Fargo is acting as an additional financial advisor and, along with BNP and HSBC, are serving as lead arrangers for the debt financing related to the transaction.

Allen & Company, J.P. Morgan and Evercore are serving as financial advisors to Warner Bros. Discovery and Wachtell, Lipton, Rosen & Katz and Debevoise & Plimpton LLP are serving as legal counsel.

A dedicated website providing ongoing information and resources about the transaction is available at netflixwbtogether.com

About Netflix, Inc.
Netflix is one of the world’s leading entertainment services offering TV series, films, games and live programming across a wide variety of genres and languages. Members can play, pause and resume watching as much as they want, anytime, anywhere, and can change their plans at any time.

About Warner Bros. Discovery
Warner Bros. Discovery is a leading global media and entertainment company that creates and distributes the world’s most differentiated and complete portfolio of branded content across television, film, streaming and gaming. Warner Bros. Discovery inspires, informs and entertains audiences worldwide through its iconic brands and products including: Discovery Channel, HBO Max, discovery+, CNN, DC, TNT Sports, Eurosport, HBO, HGTV, Food Network, OWN, Investigation Discovery, TLC, Magnolia Network, TNT, TBS, truTV, Travel Channel, Animal Planet, Science Channel, Warner Bros. Motion Picture Group, Warner Bros. Television Group, Warner Bros. Pictures Animation, Warner Bros. Games, New Line Cinema, Cartoon Network, Adult Swim, Turner Classic Movies, Discovery en Español, Hogar de HGTV and others. For more information, please visit www.wbd.com.

Important Information About the Transaction and Where to Find It

This communication may be deemed to be solicitation material in respect of the proposed transaction between WBD and Netflix (the “proposed transaction”). In connection with the proposed transaction between Netflix and WBD, WBD filed a preliminary proxy statement on Schedule 14A (the “Proxy Statement”) with the U.S. Securities and Exchange Commission (the “SEC”) on January 20, 2026. The preliminary Proxy Statement is not final and may be amended, and the definitive Proxy Statement (if and when available) will be mailed to stockholders of WBD.  WBD also intends to file a registration statement for the newly formed subsidiary of WBD (“Discovery Global”) that will be spun off from WBD prior to the closing of the proposed transaction. Each of Netflix and WBD may also file with or furnish to the SEC other relevant documents regarding the proposed transaction. This communication is not a substitute for the Proxy Statement or any other document that Netflix or WBD may file with the SEC or mail to WBD’s stockholders in connection with the proposed transaction. INVESTORS AND SECURITY HOLDERS OF NETFLIX AND WBD ARE URGED TO READ THE PROXY STATEMENT, AS WELL AS ANY OTHER RELEVANT DOCUMENTS FILED WITH THE SEC IN CONNECTION WITH THE PROPOSED TRANSACTION OR INCORPORATED BY REFERENCE INTO THE PROXY STATEMENT (INCLUDING ANY AMENDMENTS OR SUPPLEMENTS THERETO), BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION REGARDING NETFLIX, WBD, THE PROPOSED TRANSACTION AND RELATED MATTERS. The documents filed by Netflix with the SEC also may be obtained free of charge at Netflix’s website at https://ir.netflix.net/home/default.aspx. The documents filed by WBD with the SEC also may be obtained free of charge at WBD’s website at https://ir.wbd.com.

Participants in the Solicitation

Netflix, WBD and certain of their respective directors and executive officers may be deemed to be participants in the solicitation of proxies from the stockholders of WBD in connection with the proposed transaction under the rules of the SEC. Information about the interests of the directors and executive officers of WBD and other persons who may be deemed to be participants in the solicitation of stockholders of WBD in connection with the proposed transaction and a description of their direct and indirect interests, by security holdings or otherwise, will be included in the Proxy Statement, which will be filed by WBD with the SEC. Information about WBD’s directors and executive officers is set forth in WBD’s proxy statement for its 2025 Annual Meeting of Stockholders on Schedule 14A filed with the SEC on April 23, 2025, WBD’s Annual Report on Form 10-K for the year ended December 31, 2024, and any subsequent filings with the SEC. Information about Netflix’s directors and executive officers is set forth in Netflix’s proxy statement for its 2025 Annual Meeting of Stockholders on Schedule 14A filed with the SEC on April 17, 2025, and any subsequent filings with the SEC. Additional information regarding the direct and indirect interests of those persons and other persons who may be deemed participants in the proposed transaction may be obtained by reading the Proxy Statement regarding the proposed transaction when it becomes available. Free copies of these documents may be obtained as described above.

Cautionary Statement Regarding Forward-Looking Statements

This document contains “forward-looking statements” within the meaning of the federal securities laws, including Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements are based on Netflix’s and WBD’s current expectations, estimates and projections about the expected date of closing of the proposed transaction and the potential benefits thereof, their respective businesses and industries, management’s beliefs and certain assumptions made by Netflix and WBD, all of which are subject to change. In this context, forward-looking statements often address expected future business and financial performance and financial condition, and often contain words such as “expect,” “anticipate,” “intend,” “plan,” “believe,” “could,” “seek,” “see,” “will,” “may,” “would,” “might,” “potentially,” “estimate,” “continue,” “expect,” “target,” similar expressions or the negatives of these words or other comparable terminology that convey uncertainty of future events or outcomes. All forward-looking statements by their nature address matters that involve risks and uncertainties, many of which are beyond our control and are not guarantees of future results, such as statements about the consummation of the proposed transaction and the anticipated benefits thereof. These and other forward-looking statements, including the failure to consummate the proposed transaction or to make or take any filing or other action required to consummate the transaction on a timely matter or at all, are not guarantees of future results and are subject to risks, uncertainties and assumptions that could cause actual results to differ materially from those expressed in any forward-looking statements. Accordingly, there are or will be important factors that could cause actual results to differ materially from those indicated in such statements and, therefore, you should not place undue reliance on any such statements and caution must be exercised in relying on forward-looking statements. Important risk factors that may cause such a difference include, but are not limited to: (i) the completion of the proposed transaction on anticipated terms and timing, including obtaining stockholder and regulatory approvals, completing the separation of WBD’s Discovery Global business and Warner Bros. business, anticipated tax treatment, unforeseen liabilities, future capital expenditures, revenues, expenses, earnings, synergies, economic performance, indebtedness, financial condition, losses, future prospects, business and management strategies, expansion and growth of WBD’s and Netflix’s businesses and other conditions to the completion of the proposed transaction; (ii) failure to realize the anticipated benefits of the proposed transaction, including as a result of delay in completing the transaction or integrating the businesses of Netflix and WBD; (iii) Netflix’s and WBD’s ability to implement their business strategies; (iv) consumer viewing trends; (v) potential litigation relating to the proposed transaction that could be instituted against Netflix, WBD or their respective directors; (vi) the risk that disruptions from the proposed transaction will harm Netflix’s or WBD’s business, including current plans and operations; (vii) the ability of Netflix or WBD to retain and hire key personnel; (viii) potential adverse reactions or changes to business relationships resulting from the announcement, pendency or completion of the proposed transaction; (ix) uncertainty as to the long-term value of Netflix’s common stock; (x) legislative, regulatory and economic developments affecting Netflix’s and WBD’s businesses; (xi) general economic and market developments and conditions; (xii) the evolving legal, regulatory and tax regimes under which Netflix and WBD operate; (xiii) potential business uncertainty, including changes to existing business relationships, during the pendency of the proposed transaction that could affect Netflix’s or WBD’s financial performance; (xiv) restrictions during the pendency of the proposed transaction that may impact Netflix’s or WBD’s ability to pursue certain business opportunities or strategic transactions; and (xv) failure to receive the approval of the stockholders of WBD. Discussions of additional risks and uncertainties are contained in Netflix’s and WBD’s filings with the SEC, including their Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q, and the Proxy Statement filed by WBD in connection with the proposed transaction and the registration statement to be filed by Discovery Global in connection with the separation.  While the list of factors presented here is, and the list of factors presented in the Proxy Statement and registration statement will be, considered representative, no such list should be considered to be a complete statement of all potential risks and uncertainties. Unlisted factors may present significant additional obstacles to the realization of forward-looking statements. Consequences of material differences in results as compared with those anticipated in the forward-looking statements could include, among other things, business disruption, operational problems, financial loss, legal liability to third parties and similar risks, any of which could have a material adverse effect on Netflix’s or WBD’s consolidated financial condition, results of operations or liquidity. Neither Netflix nor WBD assumes any obligation to publicly provide revisions or updates to any forward-looking statements, whether as a result of new information, future developments or otherwise, should circumstances change, except as otherwise required by securities and other applicable laws.

Galbot S1 Breaks Industry Load Limits with 50KG Heavy-Duty Capacity

BEIJING, Jan. 20, 2026 /PRNewswire/ — Galbot, a global pioneer in embodied AI and general-purpose robotics, announced the launch of the Galbot S1, an industrial-grade heavy-duty embodied intelligence robot designed to meet the growing demands of modern manufacturing. This breaks the long-standing payload limit in the industry, achieving a continuous dual-arm payload of 50kg. This breakthrough robot pushes the industry’s payload limits, achieving a continuous dual-arm payload of up to 50kg. The Galbot S1 has already been successfully deployed in the core production lines of manufacturing giants such as CATL, marking a historic shift for embodied AI from experimental demonstrations to real-world industrial applications.

Galbot S1
Galbot S1

A New Era for Manufacturing: Galbot S1 Meets Real-World Heavy-Duty Needs

The manufacturing sector is facing unprecedented challenges. From heavy, long-duration tasks to dynamic environments with varying conditions, the demand for advanced, adaptable solutions has never been greater. The Galbot S1 is designed to meet these challenges, seamlessly integrating into production lines and providing a reliable, high-capacity solution.

Unlike traditional industrial robots that often rely on pre-programmed tasks or teleoperation, the Galbot S1 is purpose-built for the intense, continuous operations required in real-world industrial settings. It operates reliably in environments where dust, vibration, lighting changes, and human interaction are a part of the daily workflow.

Breaking Load Limits: A True Industry Game-Changer with 50KG Payload

The Galbot S1 represents a major breakthrough in embodied intelligence for the industrial sector. It can handle a dual-arm load of up to 50kg, offering unprecedented flexibility to meet the ever-changing needs of the manufacturing process. Operating autonomously without the need for teleoperation, the robot adapts to dynamic environments with advanced real-time responses and 360° omnidirectional obstacle avoidance. Its intelligent system ensures safety while maintaining high operational efficiency, even in challenging conditions.

Designed for Long-Term, Seamless Operations

Engineered for extended use, the Galbot S1 offers up to 8 hours of continuous operation on a single charge. Equipped with a dual-battery quick-swap design, it can autonomously replace its batteries, ensuring 24/7 operation in demanding industrial environments. This design ensures the Galbot S1 can keep up with the fast-paced requirements of modern production lines.

Powered by Galbot’s proprietary AI, the robot’s embodied handling model allows it to perform complex material handling tasks with high precision. The robot operates purely based on visual perception, eliminating the need for QR codes or labels for positioning. This means the Galbot S1 integrates seamlessly into existing production environments with minimal recalibration. It marks a significant step towards mass adoption of embodied intelligence in industrial production.

From Lab to Real-World Deployment: Validation at CATL

The ultimate validation of the Galbot S1 comes from its real-world deployment. It is currently in operation at CATL, the world’s leading battery manufacturer, handling critical heavy-load tasks on the production line. This deployment validates the Galbot S1’s ability to meet the stringent rhythm and stability requirements of advanced manufacturing. Beyond CATL, Galbot has forged partnerships with leading global manufacturers such as Bosch Group, Toyota, BAIC Group, SAIC Group, and Zeekr to explore new paradigms in flexible manufacturing powered by embodied AI.

As Galbot continues to expand its footprint in key industrial sectors, the Galbot S1 will play a pivotal role in shaping the future of manufacturing, transforming how industries approach automation and productivity. By focusing on real-world applications and scalability, Galbot is positioning itself as a leader in the evolution of embodied intelligence in the industrial sector.

About Galbot

Beijing Galbot AI Co., Ltd. is a global pioneer in embodied AI and general-purpose robotics. With R&D centers in Beijing, Shenzhen, Suzhou, and Hong Kong, Galbot brings together world-class scientists and engineers with decades of experience in embodied intelligence and robotics. Its flagship product, the Galbot G1, has been widely deployed in industrial, logistics, retail, healthcare, and education, achieving over one year of proven and stable real-world operations.

As an industry leader, Galbot is driving continuous innovation in embodied AI and accelerating the global deployment of autonomous, general-purpose humanoid robots.

LakeShore Biopharma to Hold Extraordinary General Meeting of Shareholders

BEIJING, Jan. 20, 2026 /PRNewswire/ — LakeShore Biopharma Co., Ltd (“LakeShore Biopharma” or the “Company”) (OTCPK: LSBCF; OTCPK: LSBWF), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer, today announced that it has called an extraordinary general meeting of shareholders (the “EGM”), to be held on February 12, 2026 at 11 a.m. (Beijing time) at Unit 1301, Tower 1, China Central Place, No. 81 Jianguo Road, Chaoyang District, Beijing, People’s Republic of China, to consider and vote on, among other matters, the proposal to authorize and approve the previously announced Agreement and Plan of Merger (the “Merger Agreement”) dated November 4, 2025 by and between the Company, Oceanpine Skyline Inc. (“Parent”) and Oceanpine Merger Sub Inc. (“Merger Sub”), a wholly owned subsidiary of Parent, the plan of merger required to be filed with the Registrar of Companies of the Cayman Islands (the “Plan of Merger”) and the transactions contemplated thereby, including the merger.

Pursuant to the Merger Agreement and the Plan of Merger, at the effective time of the merger, Merger Sub will be merged with and into the Company and cease to exist, with the Company being the surviving company and becoming a wholly owned subsidiary of Parent. If consummated, the merger will result in the Company becoming a privately held company, and its ordinary shares, par value US$0.0002 each (each, a “Share”), and the warrants to purchase Shares (the “Company Warrants”) will no longer be listed for quotation on any public market place or quotation system, including OTC Pink tier of the OTC Markets. In addition, the Company’s Shares and Company Warrants will cease to be registered under Section 12 of the Securities Exchange Act of 1934 following the consummation of the merger.

The Company’s board of directors, acting upon the unanimous recommendation of a special committee of independent directors established by the board of directors, authorized and approved the execution, delivery and performance of the Merger Agreement, the Plan of Merger and the consummation of the transactions contemplated thereby, and resolved to recommend that the Company’s shareholders vote FOR, among other things, the proposal to authorize and approve the Merger Agreement, the Plan of Merger, and the consummation of the transactions contemplated thereby, including the merger.

Shareholders of record as of 5 p.m. Cayman Islands time on January 16, 2026 will be entitled to attend and vote at the EGM and any adjournment thereof.

Additional information regarding the EGM and the Merger Agreement can be found in the transaction statement on Schedule 13E-3 and the definitive proxy statement attached as Exhibit (a)-(1) thereto, as amended, filed with the U.S. Securities and Exchange Commission (the “SEC”), which can be obtained, along with other filings containing information about the Company, the proposed merger and related matters, without charge, from the SEC’s website (http://www.sec.gov). Requests for additional copies of the definitive proxy statement should be directed to the Company’s Investor Relations Department by phone at +86 (10) 8920-2086 or by email at ir@lakeshorebio.com.

SHAREHOLDERS ARE URGED TO READ CAREFULLY AND IN THEIR ENTIRETY THESE MATERIALS AND OTHER MATERIALS FILED WITH OR FURNISHED TO THE SEC WHEN THEY BECOME AVAILABLE, AS THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT THE COMPANY, THE PROPOSED MERGER AND RELATED MATTERS.

The Company and certain of its directors and executive officers may, under SEC rules, be deemed to be “participants” in the solicitation of proxies from the shareholders with respect to the proposed merger. Information regarding the persons who may be considered “participants” in the solicitation of proxies is set forth in the Schedule 13E-3 transaction statement relating to the proposed merger and the definitive proxy statement attached thereto. Further information regarding persons who may be deemed participants, including any direct or indirect interests they may have, is also set forth in the definitive proxy statement.

This announcement is for information purposes only and does not constitute an offer to purchase or the solicitation of an offer to sell any securities or a solicitation of any proxy, vote or approval with respect to the proposed transaction or otherwise, nor shall it be a substitute for any proxy statement or other filings that have been or will be made with the SEC.

About LakeShore Biopharma Co., Ltd

LakeShore Biopharma, previously known as YS Biopharma, is a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer. It has developed a proprietary PIKA® immunomodulating technology platform and a new generation of preventive and therapeutic biologics targeting Rabies, Hepatitis B, Influenza, and other virus infections. The Company operates in China, Singapore, and the Philippines, and is led by a management team that combines rich local expertise and global experience in the biopharmaceutical industry.

For more information, please visit https://investors.lakeshorebio.com/.

Forward-Looking Statements

This press release contains statements that may constitute “forward-looking” statements within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, without limitation, the Company’s business plans and development, which can be identified by terminology such as “may,” “will,” “expect,” “anticipate,” “aim,” “future,” “estimate,” “intend,” “plan,” “believe,” “potential,” “continue,” “is/are likely to” or other similar expressions. LakeShore Biopharma may also make written or oral forward-looking statements in its periodic reports to the SEC, in its annual report to shareholders, in press releases and other written materials and in oral statements made by its officers, directors or employees to third parties. Statements that are not historical facts, including statements about LakeShore Biopharma’s beliefs, plans and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. A number of factors could cause actual results to differ materially from those contained in any forward-looking statement, including but not limited to the following: uncertainties as to how the Company’s shareholders will vote at the meeting of shareholders; the possibility that events may arise that result in the termination of the Merger Agreement; the possibility that competing offers will be made; the possibility that financing may not be available; the possibility that various closing conditions for the transaction may not be satisfied or waived; and other risks and uncertainties discussed in documents filed with the SEC by the Company, as well as the Schedule 13E-3 and the proxy statement filed by the Company; the Company’s goals and strategies; the Company’s future business development, financial condition and results of operations; its ability to provide efficient services and compete effectively; its ability to maintain and enhance the recognition and reputation of its brands; general economic and business conditions globally and in China and assumptions underlying or related to any of the foregoing. Further information regarding these and other risks, uncertainties or factors is included in the Company’s filings with the SEC. All information provided in this press release is as of the date of this press release, and the Company does not undertake any obligation to update any forward-looking statement as a result of new information, future events or otherwise, except as required under applicable law.

For investor inquiries, please contact:

IR Team
Tel: +86 (10) 8920-2086
Email:  ir@lakeshorebio.com 

SAG Unveils LiquidMate O: A Breakthrough UHF RFID Tagging Solution for Item-Level Traceability of Liquid-Filled Injectable Medications

Patent-pending direct-on-vial RFID label enables DSCSA-ready traceability across pharmaceutical manufacturing and hospital workflows

TAICHUNG, Jan. 20, 2026 /PRNewswire/ — SAG today announced LiquidMate O, its debut UHF RFID label and a category-defining advancement in pharmaceutical RFID and item-level traceability. Built on an innovative, patent-pending antenna architecture, LiquidMate O delivers reliable direct-on-vial RFID tagging for liquid-filled injectable medications, an application long considered one of the most technically challenging in RFID deployment. Ineffective tracking of injectable drugs continues to drive substantial losses through expired inventory, misplaced medications, and regulatory exposure—particularly for high-value or critical products. As enforcement of the U.S. Drug Supply Chain Security Act (DSCSA) accelerates, dependable, high-accuracy RFID-based medication tracking has become essential to both pharmaceutical manufacturing and hospital operations.

LiquidMate O
LiquidMate O

LiquidMate O is purpose-built to enable scalable, item-level tracking across a broad range of injectable liquid categories that have historically constrained direct-on-vial RFID adoption. Its performance has been independently validated through AXIA Lab–defined test scenarios, using representative liquid formulations and workflow conditions aligned with real clinical practice. Key capabilities include:

  • One label across multiple formulations
    Consistent RFID performance across injectable liquids with varying dielectric properties, eliminating formulation-specific labels and significantly reducing SKU complexity.
  • True direct-on-vial design
    Validated on industry-standard 10 mL glass vials with a compact 62 × 20 mm label engineered for curved, space-constrained pharmaceutical packaging.
  • Proven high-density readability
    Independently validated by AXIA Lab, achieving 100% read performance in dense, multi-vial configurations with full 360-degree omnidirectional readability.

While demand for item-level traceability continues to rise, existing RFID approaches have struggled to balance RF performance, scalability, and operational integration. Conventional direct-on-vial solutions often suffer from inconsistent performance on liquid-filled injectables due to dielectric effects, while flag-style labels, although RF-robust, pose handling, automation, and scalability challenges that limit broader adoption. LiquidMate O eliminates this trade-off by delivering a true direct-on-vial RFID solution with consistent performance across diverse injectable formulations. This enables streamlined labeling operations and improved workflow efficiency from manufacturing through point-of-care. By reducing manual scanning steps and minimizing SKU proliferation, LiquidMate O supports real-time inventory visibility, accurate dispensing, and enhanced patient safety without disrupting existing packaging lines.

“With more than two decades of experience supporting healthcare and industrial RFID applications, we have seen how reliability at the item level directly impacts compliance, efficiency, and patient safety,” said Terry Chiang, CEO of SAGLiquidMate O reflects our focus on solving the most technically complex tagging challenges in healthcare and delivering scalable, standards-based traceability solutions that pharmaceutical organizations can deploy with confidence.”

Following extensive engineering development and independent validation, LiquidMate O is now qualified for commercial deployment. Built on SAG’s deep expertise in RFID antenna design, materials science, and healthcare workflow integration, the solution is engineered to meet the stringent performance, regulatory, and scalability requirements of pharmaceutical environments. SAG is initiating structured technical engagements to support evaluation and deployment planning for next-generation item-level traceability initiatives.

About SAG

As an RFID tagging challenge enabler, SAG turns complex concepts into production-ready RFID solutions. Through deep expertise in tailored antenna design, materials science, and self-developed manufacturing systems, SAG delivers reliable RFID connectivity that performs under demanding operational and environmental constraints—enabling organizations to address complex, mission-critical workflow challenges through advanced RFID solutions.

www.sag-rfid.com
info@sag.com.tw